Skip to main content
SpringerLink
Log in

Diagnostik und moderne Behandlungsstrategien

Multiples Myelom

  • Zertifizierte Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

Zusammenfassung

In den letzten 20 Jahren hat sich die Lebenserwartung von Patienten mit multiplem Myelom aufgrund neuer Diagnosemöglichkeiten und moderner Therapieoptionen stetig verbessert. Für die Wahl der optimalen Behandlungsstrategie müssen sowohl krankheitsspezifische Faktoren als auch das individuelle Risikoprofil des Patienten, sein Alter und seine Komorbiditäten berücksichtigt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Berger D et al. Das Rote Buch, Hämatologie und Internistische Onkologie. 4. Auflage. Heidelberg, München, Landsberg, Frechen, Hamburg: ecomed MEDIZIN; 2010.

    Google Scholar 

  2. Engelhardt M et al. Das Blaue Buch. 5. Auflage. Berlin: Springer; 2014.

    Book  Google Scholar 

  3. Engelhardt M et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014;99(2):232–42.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Kleber M et al. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk. 2013;13(5):541–51.

    Article  PubMed  Google Scholar 

  5. Kortum KM et al. [Multiple myeloma]. Internist (Berl). 2013;54(8):963–77.

    Article  CAS  Google Scholar 

  6. Engelhardt M et al. Incidence of monoclonal B-cell disease in siblings of patients with multiple myeloma. Haematologica. 2006;91(2):274–6.

    PubMed  Google Scholar 

  7. Greenberg AJ et al. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia. 2012;26(4):609–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Engelhardt M et al. Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma. Anticancer Res. 2009;29(11):4745–50.

    PubMed  Google Scholar 

  9. Landgren O et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Engelhardt M et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma. 2010;51(8):1424–43.

    Article  CAS  PubMed  Google Scholar 

  11. Kyle RA et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121–7.

    Article  CAS  PubMed  Google Scholar 

  12. Mateos MV et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438–47.

    Article  CAS  PubMed  Google Scholar 

  13. Rajkumar SV et al. Diagnosis of smoldering multiple myeloma. N Engl J Med. 2011;365(5):474–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Reinhardt H et al. Innovative Substanzen und Behandlungsmethoden beim multiplen Myelom Stellenwert der subkutanen Bortezomib-Gabe. KRANKENHAUSPHARMAZIE. 2012;33(11):467–74.

    Google Scholar 

  15. Minnema MC et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant. 2008;41(9):779–84.

    Article  CAS  PubMed  Google Scholar 

  16. Avet-Loiseau H et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949–52.

    Article  PubMed  Google Scholar 

  17. Kleber M et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J. 2011;1(9):e35.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Billecke L et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013;161(1):87–94.

    Article  CAS  PubMed  Google Scholar 

  19. Child JA et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–83.

    Article  CAS  PubMed  Google Scholar 

  20. Moreau P et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–40.

    Article  PubMed  Google Scholar 

  21. Mellqvist UH et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013;121(23):4647–54.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. McCarthy PL et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–81.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Palumbo A et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112(8):3107–14.

    Article  CAS  PubMed  Google Scholar 

  24. San Miguel JF et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.

    Article  CAS  PubMed  Google Scholar 

  25. Terpos E et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18):2347–57.

    Article  CAS  PubMed  Google Scholar 

  26. Raje N et al. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res. 2011;17(6):1278–86.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Jasmin Schnerch,  Martina Kleber,  Kristina Maas-Bauer,  Georg Herget,  Karl Henne,  Tobias Baumann,  Christine König,  Milena Pantic,  Annette M. May &  Ralph Wäsch

  2. Klinik Innere Medizin I, Hämatologie, Onkologie & Stammzelltransplantation, Universitätsklinikum Freiburg, Hugstetterstr. 55, 79106, Freiburg, Deutschland

    Monika Engelhardt

Authors
  1. Jasmin Schnerch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martina Kleber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kristina Maas-Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Georg Herget
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Karl Henne
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tobias Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christine König
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Milena Pantic
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Annette M. May
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ralph Wäsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Monika Engelhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monika Engelhardt.

Additional information

Interessenkonflikt

Monika Engelhardt erhielt Forschungsunterstützung von Janssen, Celgene und MSD sowie Honorare von Janssen, MSD und Mundipharma. Martina Kleber erhielt Forschungsunterstützung von Celgene.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schnerch, J., Kleber, M., Maas-Bauer, K. et al. Diagnostik und moderne Behandlungsstrategien. Im Focus Onkologie 17, 56–63 (2014). https://doi.org/10.1007/s15015-014-0004-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-0004-x

Search

Navigation